{
  "guideline": {
    "id": "PA166265421",
    "name": "Annotation of DPWG Guideline for quetiapine and CYP3A4",
    "source": "DPWG",
    "version": 14,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265421",
    "relatedChemicals": [
      {
        "id": "PA451201",
        "name": "quetiapine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA130",
        "name": "cytochrome P450 family 3 subfamily A member 4",
        "symbol": "CYP3A4"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299124",
      "name": "Recommendation PA166299124",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451201",
          "name": "quetiapine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061487,
        "html": "<p>Indication DEPRESSION: Choose an alternative. Aripiprazole appears to be less dependent of CYP3A4 for metabolism. Olanzapine is not metabolised by CYP3A4.<br />\n&nbsp;<br />\nOTHER INDICATIONS: Use 30% of the normal dose.</p>\n"
      },
      "implications": [
        "The plasma concentration of quetiapine is 3.2-fold higher in these patients. In addition, the formation of the active metabolite N-desalkylquetiapine, which is probably\nresponsible for the antidepressant effect, should be reduced. The gene variation results in reduced activity of the enzyme CYP3A4, which converts quetiapine to N-desalkylquetiapine\nand an inactive metabolite."
      ],
      "lookupKey": {
        "CYP3A4": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299123",
      "name": "Recommendation PA166299123",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451201",
          "name": "quetiapine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061486,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of quetiapine to inactive metabolites and a metabolite with anti-depressant effect. However, the effect on the plasma concentration\nof quetiapine is limited (20% increase) and it is not known whether this has any clinical consequences. The relationship between the plasma concentration and clinical effect is\nweak for quetiapine."
      ],
      "lookupKey": {
        "CYP3A4": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299125",
      "name": "Recommendation PA166299125",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451201",
          "name": "quetiapine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061488,
        "html": "<p>The guideline does not provide a recommendation for quetiapine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on quetiapine."
      ],
      "lookupKey": {
        "CYP3A4": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37002327",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.",
      "authors": [
        "Beunk Lianne",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Guchelaar Henk Jan",
        "Houwink Elisa J F",
        "Risselada Arne",
        "Rongen Gerard A P J M",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "van der Weide Jan"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2023
    }
  ],
  "version": "2023-12-19-10-38"
}